Evaluation of the Modified Systemic Inflammation Score and Inflammatory Markers According to Stage in Colorectal Cancer

Abstract

Aim:There is recent increasing evidence of an association between inflammation and cancer. There are many studies showing that inflammatory markers can be used as prognostic markers in many types of cancer. The aim of this study was to retrospectively evaluate the effect of tumour stage on inflammatory markers and the modified systemic inflammation score (mSIS).Method:The study included 218 of 376 patients identified as having undergone curative surgery in Ankara Training and Research Hospital general surgery clinic with the diagnosis of colorectal cancer (CRC) between February 2015 and February 2020. A retrospective evaluation was made of clinical and pathological data, including age, gender, tumor type, histological tumour grade, localization of the tumor, lymph node involvement, hemogram results, albumin, carcinoembryonic antigen, and carbohydrate antigen 19-9 (CA-19-9). Laboratory data of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR)and mSIS were analyzed according to the tumor-node-metastasis stage.Results:When the cases were evaluated in terms of stage, there was a statistically significant difference in terms of Hb, albumin, neutrophil and platelet value (p<0.05). When the cases were evaluated in terms of NLR, PLR and mSIS, there was a statistically significant difference between stage I and stage II (p<0.05).Conclusion:NLR, PLR and mSIS may be predictive factors that can be used to differentiate stage 1 from other stages. Determining the pre-treatment levels of NLR, PLR and mSIS can provide useful information in early diagnosis or the evaluation of treatment options in CRC patients.

Keywords

• colorectal cancer
• msis
• nlr
• plr
• stage